Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

nce as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

About Prima BioMedPrima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

Clinical AppendixStudy Title CAN-004: A Randomized, Double-Blinded, Placebo-Controlled Phase 2/3 Trial of CVac™ (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) Following Optimal Debulking Surgery and First-line Chemotherapy

Study DesignThis is a randomized, double-blinded, placebo-controlled Phase 2/3 trial of CVac as maintenance treatment in patients with EOC following optimal debulking surgery and first-line chemotherapy. The initial planned enrollment is 750 patients. The primary analysis of irPFS is planned to be conducted after 350 irPFS events (confirmed immune-related progressive disease [irPD] or death) have occurred. The primary analysis for OS is planned to be
'/>"/>

SOURCE Prima BioMed Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... WORTH, Texas, March 22, 2012  The Board of Directors of ... innovator in advanced wound care solutions, announced today that Robert ... of the Company.  In addition, Scott A. Haire has resigned ... Executive Officer of the Company, and Deborah Jenkins Hutchinson has ...
... 22, 2012  Argon Medical Devices, Inc. announced today ... catheter, licensed from Rex Medical, LP, designed to ... treatments. "UltraStream provides clinicians with an ... life for their patients," commented George Leondis, President ...
Cached Medicine Technology:Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 2Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 3Argon Medical Devices Announces The Launch of a Unique New Chronic Hemodialysis Catheter 2
(Date:9/16/2014)... As part of Child Passenger Safety Week, which ... Amica Insurance is reminding parents and caregivers ... in the car. , According to a 2012 ... (NHTSA), 20 percent of drivers of child passengers admitted ... child restraints. However, 90 percent of those same drivers ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 Former ... well today after undergoing successful heart transplantation surgery at ... Mr. Tekulve, who spent most of his 16-year baseball ... team as a commentator for Root Sports Pittsburgh, was ... transplant surgeon, Stephen Bailey, MD, surgical director of AGH’s ...
(Date:9/16/2014)... everyday, but that doesn,t mean the findings are put ... the neonatal mortality rate is 10 times higher than ... applying an inexpensive topical solution of chlorhexidine to cleanse ... by 24 percent, many Indian parents did not receive ... that we don,t have solutions to solve major societal ...
(Date:9/16/2014)... 2014 A team of researchers at Boston University ... new model to study the motion patterns of bacteria ... relate to communication within a bacterial colony. , The ... bacteria to a microcantilever a microscopic beam anchored ... thus coupling its motion to that of the bacteria. ...
(Date:9/16/2014)... 15, 2014A prospective study that compared patient-reported outcomes ... bone metastases demonstrates that single fraction radiation therapy ... radiation therapy (MFRT) when pain, function and quality ... today at the American Society for Radiation Oncology,s ... that improvements in patients, pain, function and degree ...
Breaking Medicine News(10 mins):Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3Health News:And so they beat on, flagella against the cantilever 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4
... rest of nation, , , TUESDAY, Feb. 10 (HealthDay News) -- A ... pain has more than doubled in that state since the early ... in the country as a whole. , "We were actually ... professor of medicine at the University of North Carolina and the ...
... of Americans age 65 and older have prescription drug coverage ... according to a University of Michigan analysis. And poor seniors ... , The analysis compares drug coverage among a nationally ... both in 2004 and after the Medicare Part D prescription ...
... National Leaders in the Effort to Improve Long-Term Care ... SCAN Foundation announced today that two of America,s leading ... for the elderly, Jennie Chin Hansen, R.N., ... named to The SCAN Foundation board of directors.Bruce Chernof, ...
... in Barry Willer,s office at the University at Buffalo was ... a relatively mild traumatic brain injury, and he was doing ... best efforts, the man,s wife described him to friends as ... Willer, UB professor of psychiatry and a specialist in traumatic ...
... Government contract; $28.5 million in contract year one- ... drives revenue for first half- Earnings per share ... Strong balance sheet with $2.1 million in cash, ... Feb. 10 Sharps Compliance Corp. (OTC Bulletin ...
... The Animal Research Minute is a daily report of ... Feb. 10 The Foundation for Biomedical Research (FBR) ... radio broadcast, The Animal Research Minute, nationally after experiencing ... Minute is an educational report of the day,s medical ...
Cached Medicine News:Health News:Chronic Low Back Pain Is on the Rise 2Health News:Chronic Low Back Pain Is on the Rise 3Health News:Most seniors have drug coverage, study shows 2Health News:The SCAN Foundation Names New Members to Its Board 2Health News:The SCAN Foundation Names New Members to Its Board 3Health News:Brain-injured patients can relearn emotions 2Health News:Brain-injured patients can relearn emotions 3Health News:Brain-injured patients can relearn emotions 4Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 2Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 3Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 4Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 5Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 6Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 7Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 8Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 9Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 10Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 11Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 12Health News:Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results 13Health News:Foundation for Biomedical Research Announces National Distribution of Daily Radio Broadcast 2
... ACS allows visualization of virtually the ... essentially coaxial positioning of the lens on ... detachment surgery, repairing giant retinal tears, diagnosing ... examining the peripheral retina in a vitreous ...
... somewhat higher magnification and increased ... best suited for detailed visualization ... Central Retinal is ideal for ... membrane peeling in proliferative vitreoretinopathy ...
... MiniQuad allows visualization of virtually the ... with essentially coaxial positioning of the ... excellent for retinal detachment surgery, repairing ... anterior proliferative vitreoretinopathy and for examining ...
... Lens enhances iridectomy procedures by providing ... conventional iridectomy lens designs) with exceptional ... this lens has been increased from ... The MagPlus comes standard with LaserWindow ...
Medicine Products: